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http://dx.doi.org/10.1016/j.jmu.2013Our objective was to assess the diagnostic accuracy of three-dimensional power Doppler
(3DPD) indices (vascularization index, flow index, vascularization flow index) in distinguishing
between benign and malignant breast masses by performing a systematic review of the current
literature. The following databases were searched from their inception until October 18, 2012:
Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects,
Medical Literature Analysis and Retrieval System Online, Embase, PsycINFO, Cumulative Index
to Nursing and Allied Health Literature, and Literatura Latino-Americana e do Caribe em Cieˆn-
cias da Sau´de. Studies were considered eligible if they met the following criteria: (1) they eval-
uated the diagnostic accuracy of at least one of the 3D Doppler indices to differentiate benign
from malignant breast masses; (2) cytology or/and histology was used as the reference stan-
dard to determine malignancy; (3) the number of true positives, false positives, true negatives,
and false negatives could be retrieved. This search resulted in only one eligible study. This
study evaluated a relatively large sample size, and we did not have any concern regarding
applicability or risk of bias when evaluating its quality. The results show that adding 3DPD
indices only slightly improved the diagnostic test accuracy in distinguishing benign and malign
breast masses in women with suspicious breast masses requiring biopsy. We concluded that
although 3DPD indices seem to be able to help in distinguishing between benign and malignant
breast masses, there is still insufficient evidence to suggest using this method in clinicalP. Martins, Department of Obstetrics and Gynecology, Medical School of Ribeira˜o Preto, University of
os Bandeirantes, 3900, 8 andar. Ribeira˜o Preto, Sa˜o Paulo CEP 14049-900, Brazil.
com (W.P. Martins).
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Description of condition
Breast cancer is the most frequently diagnosed cancer in
women, and the leading cause of cancer death in females
worldwide and the second leading cause of death in our
society [1]. It accounts for 23% (1.38 million) of the total
new cancer cases [1]. Diagnosis in early stages is associated
with better survival rates, and the diagnosis of preclinical
cases may be beneficial [2]. Breast mass is an early finding
in breast cancer patients [3]; however, approximately 90%
of the masses are benign tumors, such as fibroadenomas
and cysts [4]. Risk factors for malignancy include age, his-
tory of breast cancer, and breast cancer in first-degree
relatives [4]. In this context, noninvasive tools that accu-
rately separate benign from malignant masses could
potentially prevent unnecessary biopsies.
Description of the intervention and how it might
work
Three-dimensional power Doppler ultrasonography (3DPD)
allows the examination and quantification of blood flow
within corporal structures. This information can then be
quantified to derive three indices of vascularity: the
vascularization index (VI), the flow index (FI), and the
vascularization flow index (VFI). VI is the ratio of color
voxels to all voxels in a given volume of interest; FI is the
mean value of all color voxels in the analyzed volume; and
VFI is a combination of the two, calculated by multiplying
the values together and dividing the result by 100 [5].
Several studies have been published about these indices in
the past decade, especially in Ob-Gyn [6], and some au-
thors have demonstrated that these 3DPD indices clearly
showed a correlation with real blood flow in experimental
models [7e9]. Because angiogenesis plays a fundamental
role in the genesis and tumor growth [10], it is plausible
that Doppler indices of 3D ultrasound can help discriminate
between benign and malignant breast masses. However,
several studies reported some limitations of these indices,
particularly the dependency of machine settings and
attenuation [11e14].
Why it is important to conduct this review
Although some studies have already assessed the 3DPD
indices in breast masses, there is still no recommendation
for its use in clinical practice. The lack of consensus about
its clinical usefulness highlights the need for a systematic
review and meta-analysis of the diagnostic accuracy of this
method in order to obtain more robust evidence about ofthe value of the incorporation of 3DPD indices during
evaluation of breast masses.Objectives
We conducted this review to assess the diagnostic accuracy
of 3DPD indices (VI, FI, VFI) in distinguishing between
benign and malignant breast masses.Methods
Eligibility criteria
Studies were considered eligible if they met the following
criteria: (1) they evaluated the diagnostic accuracy of at
least one of the 3D Doppler indices to differentiate benign
from malignant breast masses; (2) cytology or/and histol-
ogy was used as the reference standard to determine ma-
lignancy; (3) the number of true positives, false positives,
true negatives, and false negatives could be retrieved by
reading the manuscript or contacting the study’s corre-
sponding author.Information sources and search
We searched the following electronic databases: Cochrane
Central Register of Controlled Trials (CENTRAL), Database of
Abstracts of Reviews of Effects (DARE), Medical Literature
Analysis and Retrieval System Online (MEDLINE), Embase,
PsycINFO; Cumulative Index to Nursing and Allied Health
Literature (CINAHL); and Literatura Latino-Americana e do
Caribe em Cieˆncias da Sau´de (LILACS). In addition, we hand-
searched the reference list of the included articles. We did
not impose any publication date or language limits for the
searches. We used the following terms adjusting for each
database when necessary: [(breast) or (mammary)] and
(Doppler) and [(three-dimensional) or (three dimensional) or
(3D) or (3 D) or (3-D)].Study selection
Two independent reviewers (G.L.M. and A.H.M.) scanned
the retrieved titles and abstracts, selecting those that
clearly do not meet the eligibility criteria; disagreements
between reviewers were resolved by consulting a third
author (W.P.M.), who also obtained a full copy of the arti-
cles. The full articles were then examined for eligibility
independently by two reviewers (G.L.M. and A.H.M.), and
any disagreements between reviewers were resolved by
consulting a third author (WPM).
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Data were extracted independently by two authors (G.L.M.
andW.P.M.) using a data extraction form designed and pilot-
tested by the authors. Disagreements between reviewers
were resolved by consulting a third author (C.O.N.). The
names of article authors and titles of the included studies
were juxtaposed to seek for duplicate publication. Where
articles were related to the same participantsdtotally or
partiallydthey were considered as a single study. In such
cases, data were extracted from the main article and addi-
tional details were derived from secondary articles.
We extracted the following items from the included
studies: author; publication year; country; number of par-
ticipants; mean age of participants; number of benign and
malignant breast tumors; number of true positives, false
positives, true negatives, false negatives.
Quality assessment
The quality of the included study was evaluated by the
revised tool for the quality assessment of diagnostic accu-
racy studies (QUADAS-2) [15].
Data synthesis
Data was combined using the hierarchical summary receiver
operator characteristics method and the bivariate normal
random-effects analysis of sensitivity and specificity within
the Metandi module in the STATA 11 statistical software
(Statacorp LP, College Station, TX, USA). The Metandi plot
would be used for graphical representation. However, only
one study was included, and the data could not be pooled.
The results of the included study were then presented.Fig. 1 Study flEvaluation of heterogeneity, sensitivity analysis,
and publication bias
Heterogeneity, sensitivity analysis, and risk of publication




The electronic search was last performed on October 18,
2012, and a total of 662 records were retrieved. We
excluded 644 records on the basis of title and abstract: 49
were duplicates and 595 clearly did not meet the eligibility
criteria. We obtained 18 full-text articles, from which 12
were excluded: 10 did not report VI, FI, or VFI [16e25], and
two full-text articles were related to studies evaluating
only confirmed breast cancer tumors [26,27]. Six full-text
articles referred to studies that would met our inclusion
criteria [28e33]; however, these six full-text articles
included an overlapping population of women. This was
confirmed by e-mail contact, and these six full-text articles
were then considered as a single study (Fig. 1). The article
with the largest sample size was considered the main
report [33].
Characteristics of the included study
The study included in this review was conducted in Taiwan
(single center). Two hundred patients were consecutively
enrolled in this study during a 13-month period (January 2003
to February 2004). All women had a scheduled biopsydfineow diagram.
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biopsydfor suspicious mass. The result of this biopsy was
used as the standard test to discriminate benign and malig-
nant masses. Five patients with a breast mass larger than 3.0
cmwere excluded because the authors could not include the
tumor plus the 3-mm surrounding tissue in only one Power
Doppler 3D dataset. A total of 102 participants with benign
breast tumors and 93 with malignant breast tumors were
analyzed.
All participants were scanned using the Voluson730 ul-
trasound system (GE Healthcare, Zipf, Austria), which was
equipped with a 6 MHz to 12 MHz 3D/4D transducer. Power
Doppler static 3D datasets were acquired with 20 sweep
angles using fixed preinstalled power Doppler settings:
midfrequency, pulse repetition frequency Z 0.9 kHz;
gain Z e0.6; wall motion filter Z “low 1”. The probe was
held still, and the women were asked to hold their breath
for about 20 s, if possible, as the scanner generated the 3D
volume. Acquired 3D volumes were stored for subsequent
offline analysis. The tumor volume was contoured using
VOCAL in the manual mode and a rotation step of 30: VI,
FI, and VFI were estimated from the tumor and also from an
outer shell of 3 mm of the surrounding tissue; the latter was
not considered in this review.
The median age of the participants was 40 years (range,
17e72 years) and 49 years (range, 31e80 years) for benign
and malignant breast tumors, respectively. The median
tumor diameterwas 14.0mm (range, 5e30mm) and 18.8mm
(range, 5e30 mm), and the median tumor volume was 0.57
cm3 (range, 0.03e9.09 cm3) and 3.13 cm3 (range, 0.29e16.32
cm3), for benign and malignant breast tumors, respectively.
Accuracy of VI, FI, and VFI for distinguishing
between malignant and benign masses
The median VI was 0.11 (range, 0e6.27) and 1.07 (range,
0e15.45) for benign and malignant tumors, respectively. The
median FI was 21.21 (range, 0e38.17) and 29.07 (range,
0e44.05), and the median VFI was 0.03 (range, 0e1.84) andTable 1 Univariate and multivariate logistic regression analyses
malignant breast masses.
AUROC 95% CI Sens. (%
Univariate models
Age 0.79 0.73e0.84 66.7
Breast tumor volume 0.87 0.83e0.90 67.7
VI from breast tumor 0.78 0.72e0.83 51.6
FI from breast tumor 0.82 0.77e0.86 73.1
VFI from breast tumor 0.79 0.73e0.84 52.7
Multivariate models
Age þ Volume 0.91 0.89e0.93 72.0
Age þ Volume þ FI 0.93 0.90e0.94 82.8
95% CI Z 95% confidence interval; Accur. Z accuracy; AUROC Z are
negative; FP Z false positive; Sens. Z sensitivity; Spec. Z specificit
dimensional power Doppler indices vascularization index, flow inde
ultrasound measurement of the mass using manual contouring.
Note. The data in row ‘VFI from breast tumor’ are from “Intra-t
tumor: dependent on age and volume” by Y-H Hsia, S-J Kuo, W-
p. 88e95. Copyright 2007, World Federation for Ultrasound in M0.32 (range, 0e6.12) for benign and malignant tumors,
respectively. The areas under the receiver operating charac-
teristic curves (AUROC) [with its 95% confidence interval (CI)],
sensitivity, specificity, accuracy, number of true positives,
true negatives, false positives, and false negatives for age,
mass diameter, and volume, and for the 3DPD indices are re-
ported in Table 1. All evaluated parameters had some value in
differentiating between benign and malignant masses as the
95% CI of the AUROC curves did not overlap 0.50.
Individually,massvolumewas slightlybetter than theother
parameters: AUROC Z 0.87 (95% CI, 0.83e0.90). However,
better performance was achieved when some of these pa-
rameters were added up. The multivariate logistic regression
analysis showed that adding patient age and breast volume
increased the AUROC to 0.91 (95% CI, 0.89e0.93). When add-
ing FI to this model (age þ mass volume þ FI from tumor), a
relevant improvement was noticed in terms of sensitivity
(72.0% vs. 82.8%, without vs. with FI, respectively) and accu-
racy (79.5% vs. 85.1%); however, there was still an overlap in
the 95% CI of the AUROC (Table 1).
Risk of bias (QUADAS 2)
The included study was considered at low risk of bias
related to patient selection, index test, reference stan-
dard, and flow and timing. No concern regarding applica-
bility on patient selection, index test, or reference
standard was identified; in addition, the risk of bias of all
four domains was judged to be low. The characteristics of
the included study and all QUADAS-2 judgments are pre-
sented in Table 2 [33].Discussion
Summary of main results
Only one study could be included in this systematic review.
This study evaluated a relatively large sample size, and weof the studied parameters in the differentiation of benign and
) Spec. (%) Accur. (%) TP TN FP FN
77.5 72.3 62 79 23 31
89.2 79.0 63 91 11 30
90.2 71.8 48 92 10 45
72.5 72.8 68 74 28 25
90.2 72.3 49 92 10 44
86.3 79.5 67 88 14 26
87.3 85.1 77 89 13 16
a under the receiver operating characteristic curve; FN Z false
y; TN Z true negative; TP Z true positive; VI, FI, VFI Z three-
x, and vascularization-flow index; Volume Z three-dimensional
umor flow index can predict the malignant potential of breast
M Liang, Huang YL, Chen DR., 2008, Ultrasound Med Biol, 34,
edicine & Biology. Adapted with permission.
Table 2 QUADAS-2 risk of bias and applicability judgments for the included study.
Study: Hsiao et al [33]
Patient selection
Description A total of 200 women were recruited consecutively during a 13-mo period
(January 2003eFebruary 2004). All had been scheduled to undergo excisional
or percutaneous needle biopsy on the basis of suspicious mammographic or US
findings. Excluded if tumor >3 cm, because it did not fit in one 3D volume
(5 women).
Risk of bias Low
Concerns regarding applicability Low
Index test
Description Ultrasound setting maintained the same for all scans. The patients had a biopsy
scheduled; the reference standard text had not been performed at that point.
No threshold was applied.
Risk of bias Low
Concerns regarding applicability Low
Reference standard
Description Women underwent fine needle aspiration cytology, core biopsy and/or
excisional biopsy.
Risk of bias Low
Concerns regarding applicability Low
Flow and timing
Description Five of 200 women were excluded because of the impossibility of performing
the index test. Timing between US and biopsy was not described.
Risk of bias Low
130 G.L. Martinez et al.did not have any concern regarding applicability or risk of
bias when evaluating its quality. However, this included
study shows that adding 3DPD indices only slightly improved
the diagnostic test accuracy in distinguishing benign and
malign breast masses in women with suspicious breast
masses requiring biopsy.
Limitations
Although we performed an extensive search, only one study
could be included in this review. The results obtained are
therefore limited by a potential lack of external validity to
other healthcare centers. It means that these results are
limited by many factors such as the characteristics of the
population studied, experience of the observers, and ul-
trasound machine settings. However, the malignancy rate
observed by this study is close to the expected level: 47.7%
of the tumors were malignant, which is comparable to the
proportion of malignancies (33%) observed in women un-
dergoing breast biopsy after screening mammography [34].
One should still consider the limitations of 3DPD indices,
particularly the need for special ultrasound machines and
training [6], and the high dependency of machine settings
and attenuation [35,36]. New 3DPD indices and standardi-
zations that at least theoretically overcome these limita-
tions are currently being investigated [12,13,37,38];
hopefully, in a few years we will have studies evaluating
their clinical utility in breast masses.
Conclusions
Although3DPD indices seemtobeable tohelp indistinguishing
between benign and malignant breast masses, there is stillinsufficient evidence to suggest using this method in clinical
practice. More good quality studies evaluating the diagnostic
accuracy of this method are still required.
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